

Supplementary Online Content

Spijkerman J, Veenhoven RH, Wijmenga-Monsuur AJ, Elberse KEM, Van Gageldonk PGM, Knol MJ, De Melker HE, Sanders EAM, Schouls LM and Berbers GAM.

Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial. *JAMA*. doi:10.1001/jama.2013.228052.

eTable 1A. Pneumococcal serotype-specific antibody GMCs and antibody concentrations >0.35µg/ml measured 1 month post-booster

eTable 1B. Pneumococcal serotype-specific antibody GMCs and antibody concentrations >0.35µg/ml measured 1 month after the primary series.

eTable 1C. Pneumococcal serotype-specific antibody GMCs and antibody concentrations >0.35µg/ml measured at 8 months of age.

eTable 1D. Pneumococcal serotype-specific antibody GMCs and antibody concentrations >0.35µg/ml measured pre-booster.

eTable 2A. Avidity indices of pneumococcal serotype-specific IgG antibodies measured 1 month post-booster.

eTable 2B. Avidity indices of pneumococcal serotype-specific IgG antibodies measured 1 month after the primary series.

eTable 2C. Anti-pneumococcal serotype-specific opsonophagocytic activity (OPA) titers and percentage of infants with OPA titer $\geq 1:8$ measured 1 month after the primary series measured for serotypes 6B, 14, 19A and 23F.

eTable 3A. Immunogenicity of routine vaccine (DTPa-IPV-Hib) administered at 2, 3, 4 and 11-12 months of age and given concomitantly with or without PCV-13 measured 1 month after the booster dose.

eTable 3B. Immunogenicity of routine vaccine (DTPa-IPV-Hib) administered at 2, 3, and 4 months of age and given concomitantly with or without PCV-13 measured pre-booster.

eFigure 1A. Relative cumulative distribution curves of the serotype-specific IgG concentrations per schedule one month post-booster.

eFigure 1B. Relative cumulative distribution curves of the serotype-specific IgG concentrations per schedule one month post-primary series.

eFigure 2. Longitudinal course of GMCs after primary series up to the booster per schedule per serotype.

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1A. Pneumococcal serotype-specific antibody GMCs and antibody concentrations >0.35 µg/ml measured 1 month post-booster.

	Schedules								P-value ^b					
	2-4-6 (n=95) ^a		3-5 (n=91)		2-3-4 (n=89)		2-4 (n=93)		2-4-6 vs		3-5 vs		2-3-4 vs	
Serotype	GMC (95% CI)	% ≥0.35	GMC (95% CI)	% ≥0.35	GMC (95% CI)	% ≥0.35	GMC (95% CI)	% ≥0.35	3-5	2-3-4	2-4	2-3-4	2-4	2-4
1	6.0 (4.7-7.5)	98	11.7 (9.6-14.3)	100	6.2 (5.0-7.6)	100	7.8 (6.6-9.3)	100	<.001		.36	<.001	.03	.66
3	1.6 (1.3-1.9)	71	2.1 (1.7-2.5)	100	1.7 (1.5-2.0)	99	2.1 (1.7-2.4)	98	.10		.12	.61		.71
4	4.5 (3.8-5.4)	96	5.6 (4.5-6.9)	99	4.2 (3.5-5.0)	100	4.4 (3.7-5.2)	99	.68			.19	.42	
5	6.5 (5.5-7.8)	100	7.0 (5.6-8.9)	99	5.0 (4.2-5.9)	99	5.3 (4.5-6.1)	100		.25	.62	.06	.18	
6A	17.1 (14.6-20.0)	99	18.2 (15.4-21.5)	100	15.0 (12.4-18.3)	100	19.9 (16.7-23.7)	100				.74		.15
6B	8.5 (7.1-10.2)	100	7.3 (5.6-9.5)	98	6.2 (4.5-8.4)	94	5.1 (3.8-6.7)	97		.50	.03		.34	
7F	11.4 (9.6-13.5)	100	10.9 (8.7-13.5)	99	8.7 (7.4-10.3)	100	9.1 (7.9-10.4)	100		.21	.41	.50	.90	
9V	5.8 (4.9-6.9)	100	6.7 (5.7-8.0)	100	5.9 (5.0-6.9)	100	5.8 (5.0-6.7)	100						
14	7.9 (6.4-9.6)	97	8.8 (7.2-10.6)	98	9.5 (7.6-12.0)	97	8.9 (7.3-10.8)	100						
18C	10.2 (8.2-12.7)	99	9.2 (7.5-11.3)	99	6.5 (5.4-7.8)	100	6.6 (5.7-7.7)	99		.005	.007	.07	.09	
19A	3.9 (3.2-4.8)	90	4.5 (3.5-5.7)	99	5.2 (4.1-6.8)	97	4.2 (3.2-5.5)	95		.60				
19F	15.7 (13.1-18.9)	100	18.3 (14.9-22.5)	100	19.5 (15.9-24.1)	100	17.4 (13.6-22.1)	100		.90				
23F	10.9 (9.0-13.3)	100	8.5 (7.0-10.4)	100	7.3 (5.8-9.2)	99	7.2 (5.9-8.8)	99	.56	.04	.03			

^a For serotype 4, 5, 6A and 14 IgG levels were available for 94 participants; ^b Differences in GMCs between groups were analyzed using ANOVA and corrected for 6 multiple comparisons using Bonferroni. An adjusted p-value of <0.05 is considered statistically significant (in bold).

eTable 1B. Pneumococcal serotype-specific antibody GMCs and antibody concentrations >0.35 µg/ml measured 1 month after the primary series.

	Schedules								P-value ^a					
	2-4-6 (n=89)		3-5 (n=90)		2-3-4 (n=88)		2-4 (n=89)		2-4-6 vs			3-5 vs		2-3-4 vs
Serotype	GMC (95% CI)	% ≥0.35	GMC (95% CI)	% ≥0.35	GMC (95% CI)	% ≥0.35	GMC (95% CI)	% ≥0.35	3-5	2-3-4	2-4	2-3-4	2-4	2-4
1	3.7 (3.1-4.5)	100	4.6 (3.7-5.7)	97	1.4 (1.1-1.7)	96	2.3 (1.8-2.9)	93	.95	<.001	.008	<.001	<.001	.01
3	1.6 (1.4-2.0)	98	2.8 (2.3-3.3)	99	2.2 (1.9-2.6)	99	1.5 (1.3-1.7)	96	<.001	.05		.54	<.001	.004
4	1.4 (1.1-1.7)	94	1.5 (1.2-1.8)	93	0.6 (0.5-0.8)	76	0.7 (0.6-0.9)	82		<.001	<.001	<.001	<.001	
5	3.7 (3.0-4.6)	98	3.1 (2.4-3.8)	97	1.7 (1.3-2.2)	90	1.5 (1.2-1.9)	92		<.001	<.001	.002	<.001	
6A	7.8 (6.6-9.4)	100	3.4 (2.6-4.4)	93	1.9 (1.4-2.6)	91	2.1 (1.6-2.7)	87	<.001	<.001	<.001	.009	.03	
6B	1.9 (1.4-2.7)	88	0.2 (0.1-0.3)	30	0.3 (0.2-0.4)	44	0.1 (0.1-0.1)	11	<.001	<.001	<.001		.001	<.001
7F	6.7 (5.6-7.9)	100	5.5 (4.5-6.8)	99	2.7 (2.2-3.3)	99	3.4 (2.8-4.1)	97		<.001	<.001	<.001	.002	.51
9V	2.6 (2.1-3.2)	98	2.1 (1.7-2.6)	96	1.7 (1.4-2.1)	96	1.1 (0.9-1.5)	80		.06	<.001		.001	.08
14	4.0 (3.2-5.1)	96	3.8 (3.0-4.9)	94	2.4 (1.9-3.2)	92	2.5 (2.0-3.3)	90		.03	.06	.08	.15	
18C	4.7 (3.8-5.7)	99	3.3 (2.6-4.2)	94	2.2 (1.7-2.8)	93	2.3 (1.8-3.0)	91	.23	<.001	<.001	.12	.26	
19A	1.9 (1.5-2.4)	92	1.7 (1.3-2.3)	88	1.8 (1.4-2.2)	90	0.9 (0.7-1.1)	76			<.001		<.001	<.001
19F	5.9 (4.8-7.3)	100	5.0 (3.8-6.7)	94	7.0 (5.2-9.2)	98	2.8 (2.2-3.7)	97			<.001	.48	.01	<.001
23F	3.7 (2.9-4.7)	97	0.8 (0.6-1.1)	68	1.1 (0.8-1.5)	83	0.4 (0.3-0.6)	58	<.001	<.001	<.001	.59	.02	<.001

^a Differences in GMCs between groups were analyzed using ANOVA and corrected for 6 multiple comparisons using Bonferroni. An adjusted p-value of <0.05 is considered statistically significant (in bold).

eTable 1C. Pneumococcal serotype-specific antibody GMCs and antibody concentrations >0.35 µg/ml measured at 8 months of age.

Serotype	Schedules								P-value ^a					
	2-4-6 (n=87)		3-5 (n=87)		2-3-4 (n=90)		2-4 (n=93)		2-4-6 vs			3-5 vs		2-3-4 vs
	GMC (95% CI)	% ≥0.35	GMC (95% CI)	% ≥0.35	GMC (95% CI)	% ≥0.35	GMC (95% CI)	% ≥0.35	3-5	2-3-4	2-4	2-3-4	2-4	2-4
1	2.0 (1.6-2.4)	98	1.7 (1.4-2.1)	95	0.6 (0.5-0.7)	79	0.8 (0.7-1.0)	87		<.001	<.001	<.001	<.001	.04
3	0.9 (0.7-1.0)	93	1.1 (0.9-1.3)	93	0.6 (0.5-0.7)	78	0.5 (0.4-0.5)	59	.55	.004	<.001	<.001	<.001	.12
4	0.8 (0.7-0.9)	84	0.6 (0.5-0.7)	72	0.3 (0.2-0.3)	39	0.3 (0.3-0.3)	36	.09	<.001	<.001	<.001	<.001	
5	2.4 (2.0-3.0)	94	1.4 (1.1-1.7)	94	0.7 (0.6-0.9)	83	0.7 (0.6-0.9)	80	.001	<.001	<.001	<.001	<.001	
6A	4.3 (3.6-5.2)	100	1.8 (1.5-2.2)	95	0.9 (0.7-1.2)	90	1.1 (0.9-1.4)	85	<.001	<.001	<.001	<.001	.01	.97
6B	1.2 (0.9-1.7)	84	0.3 (0.2-0.3)	39	0.3 (0.2-0.3)	46	0.1 (0.1-0.2)	22	<.001	<.001	<.001		.007	.01
7F	4.3 (3.7-5.1)	100	3.0 (2.6-3.5)	100	1.3 (1.1-1.6)	94	1.7 (1.4-1.9)	97	.01	<.001	<.001	<.001	<.001	.29
9V	1.5 (1.2-1.8)	97	0.9 (0.7-1.0)	86	0.6 (0.5-0.7)	79	0.5 (0.5-0.6)	76	<.001	<.001	<.001	.007	.001	
14	3.0 (2.4-3.7)	95	2.5 (2.0-3.0)	95	1.7 (1.4-2.2)	91	1.5 (1.2-1.9)	91		0.005	<.001	.16	.02	
18C	2.7 (2.2-3.3)	98	1.3 (1.1-1.5)	93	0.7 (0.6-0.9)	80	0.8 (0.7-0.9)	90	<.001	<.001	<.001	<.001	.004	
19A	1.2 (1.0-1.5)	87	1.0 (0.8-1.2)	81	0.7 (0.6-0.9)	84	0.5 (0.4-0.7)	62	.78	.009	<.001	0.58	.001	.15
19F	3.5 (2.9-4.3)	99	2.1 (1.6-2.6)	95	2.0 (1.6-2.5)	96	1.1 (0.8-1.4)	89	.009	.003	<.001		.001	0.002
23F	2.0 (1.6-2.5)	97	0.5 (0.4-0.6)	55	0.4 (0.3-0.5)	52	0.3 (0.2-0.3)	36	<.001	<.001	<.001		.01	.30

^a Differences in GMCs between groups were analyzed using ANOVA and corrected for 6 multiple comparisons using Bonferroni. An adjusted p-value of <0.05 is considered statistically significant (in bold).

eTable 1D. Pneumococcal serotype-specific antibody GMCs and antibody concentrations >0.35 µg/ml measured pre-booster.

	Schedules								P-value ^a					
	2-4-6 (n=94)		3-5 (n=89)		2-3-4 (n=88)		2-4 (n=88)		2-4-6 vs			3-5 vs		2-3-4 vs
Serotype	GMC (95% CI)	% ≥0.35	GMC (95% CI)	% ≥0.35	GMC (95% CI)	% ≥0.35	GMC (95% CI)	% ≥0.35	3-5	2-3-4	2-4	2-3-4	2-4	2-4
1	1.2 (1.1-1.4)	96	1.1 (0.9-1.3)	98	0.7 (0.6-0.8)	85	0.8 (0.7-0.9)	85		<.001	<.001	<.001	0.003	
3	0.3 (0.3-0.4)	38	0.4 (0.3-0.4)	47	0.2 (0.2-0.3)	21	0.3 (0.2-0.3)	22	.44	.03	.07	<.001	<.001	
4	0.5 (0.4-0.6)	69	0.4 (0.4-0.5)	55	0.3 (0.2-0.3)	35	0.3 (0.2-0.3)	34	.23	<.001	<.001	.001	<.001	
5	1.0 (0.8-1.2)	92	0.8 (0.7-0.9)	85	0.5 (0.5-0.6)	71	0.5 (0.5-0.6)	71	.27	<.001	<.001	.001	<.001	
6A	1.9 (1.7-2.2)	100	1.4 (1.1-1.6)	94	0.9 (0.7-1.1)	90	1.0 (0.8-1.2)	88	.03	<.001	<.001	.02	.07	
6B	0.7 (0.6-0.9)	80	0.4 (0.3-0.5)	52	0.4 (0.3-0.5)	65	0.2 (0.2-0.3)	35	<.001	.001	<.001		.003	.001
7F	2.4 (2.1-2.8)	100	2.2 (1.9-2.5)	99	1.2 (1.0-1.4)	97	1.4 (1.2-1.6)	96		<.001	<.001	<.001	<.001	
9V	0.8 (0.7-0.9)	86	0.6 (0.5-0.7)	79	0.5 (0.4-0.6)	76	0.4 (0.4-0.5)	63	.01	<.001	<.001	.30	.007	
14	2.1 (1.7-2.5)	96	1.7 (1.4-2.0)	96	1.6 (1.3-1.9)	97	1.1 (0.9-1.4)	89	.66	.19	<.001		.01	.07
18C	1.1 (1.0-1.3)	94	0.8 (0.7-0.9)	91	0.6 (0.5-0.7)	78	0.6 (0.5-0.7)	82	.002	<.001	<.001	.10	.01	
19A	0.8 (0.6-0.9)	82	0.7 (0.6-0.9)	78	0.7 (0.6-0.9)	81	0.6 (0.4-0.7)	61			0.33			.94
19F	2.3 (1.8-2.8)	98	1.8 (1.4-2.4)	90	2.0 (1.6-2.7)	100	1.3 (1.0-1.9)	88			0.05		.85	.23
23F	0.9 (0.7-1.1)	85	0.4 (0.4-0.5)	60	0.4 (0.3-0.5)	49	0.3 (0.3-0.4)	47	<.001	<.001	<.001		.37	

^a Differences in GMCs between groups were analyzed using ANOVA and corrected for 6 multiple comparisons using Bonferroni. An adjusted p-value of <0.05 is considered statistically significant (in bold).

eTable 2A. Avidity indices of pneumococcal serotype-specific IgG antibodies measured 1 month post-booster.

Serotype	Schedules				P-value ^a					
	2-4-6 (n=40)	3-5 (n=40)	2-3-4 (n=40)	2-4 (n=40)	2-4-6 vs			3-5 vs		2-3-4 vs
	Mean (95% CI)	Mean (95% CI)	Mean (95% CI)	Mean (95% CI)	3-5	2-3-4	2-4	2-3-4	2-4	2-4
1	52 (46-58)	59 (54-64)	57 (50-63)	57 (52-61)			.38			
3	44 (40-48)	44 (39-48)	43 (38-47)	39 (35-43)			.73		.87	
4	65 (59-71)	64 (59-70)	71 (66-77)	65 (61-69)		.58		.40		.49
5	72 (67-77)	78 (73-83)	71 (65-77)	76 (73-80)	.50			.31		.83
6A	66 (61-70)	63 (59-68)	63 (57-68)	60 (54-66)			.88			
6B	59 (54-63)	60 (55-65)	60 (55-65)	54 (48-60)					.65	.61
7F	78 (75-81)	81 (77-85)	79 (76-82)	76 (73-79)			.98		.12	
9V	75 (72-78)	78 (74-82)	82 (78-86)	78 (74-81)		.07		.94		.71
14	72 (66-77)	73 (68-78)	71 (65-76)	73 (69-77)						
18C	70 (67-74)	73 (69-76)	78 (75-82)	76 (72-80)		.01	.10	.22	.99	
19A	61 (56-67)	62 (56-68)	68 (62-73)	65 (59-71)		.71		.98		
19F	60 (55-66)	61 (54-67)	66 (59-72)	63 (57-69)						
23F	70 (65-74)	73 (68-78)	73 (68-77)	69 (65-73)						

AI; avidity index. N indicates maximum number of infants with available results; actual number of infants included in the analysis varies slightly per serotype. ^aDifferences in AI between groups were analyzed using ANOVA and corrected for 6 multiple comparisons using Bonferroni. An adjusted p-value of <0.05 is considered statistically significant (in bold).

eTable 2B. Avidity indices of pneumococcal serotype-specific IgG antibodies measured 1 month after the primary series.

Serotype	Schedules				P-value ^a					
	2-4-6 (n=40)	3-5 (n=40)	2-3-4 (n=40)	2-4 (n=40)	2-4-6 vs			3-5 vs		2-3-4 vs
	Mean (95% CI)	Mean (95% CI)	Mean (95% CI)	Mean (95% CI)	3-5	2-3-4	2-4	2-3-4	2-4	2-4
1	38 (34-43)	37 (34-41)	36 (32-41)	36 (32-40)						
3	38 (34-42)	32 (28-36)	26 (24-29)	38 (34-42)	.18	<.001		.17	.22	<.001
4	54 (49-59)	50 (46-54)	41 (36-45)	51 (47-55)		<.001		.02		.005
5	66 (61-72)	63 (58-68)	55 (49-60)	61 (55-66)		.02	.87	.13		.66
6A	44 (40-49)	29 (25-33)	22 (18-25)	28 (24-32)	<.001	<.001	<.001	.07		.14
6B	35 (31-39)	33 (27-38)	25 (21-30)	35 (28-41)		.05		.24		.06
7F	71 (68-75)	66 (63-70)	63 (60-66)	65 (61-68)	.24	0.003	.03	.83		
9V	63 (60-66)	56 (52-60)	54 (50-59)	55 (52-59)	.04	0.006	.02			
14	52 (45-59)	50 (45-55)	48 (42-54)	52 (47-58)						
18C	60 (57-64)	55 (51-59)	43 (39-47)	54 (50-58)	.27	<.001	.15	<.001		<.001
19A	52 (49-56)	49 (46-53)	38 (34-42)	50 (45-54)		<.001		<.001		<.001
19F	53 (48-58)	46 (41-50)	36 (31-41)	47 (42-51)	.16	<.001	.43	.03		.007
23F	54 (50-58)	45 (41-49)	37 (33-41)	45 (40-49)	.02	<.001	.01	.04		.05

AI; avidity index. N indicates maximum number of infants with available results; actual number of infants included in the analysis varies slightly per serotype. ^a Differences in AI between groups were analyzed using ANOVA and corrected for 6 multiple comparisons using Bonferroni. An adjusted p-value of <0.05 is considered statistically significant (in bold).

eTable 2C. Anti-pneumococcal serotype-specific opsonophagocytic activity (OPA) titers and percentage of infants with OPA titer $\geq 1:8$ measured 1 month after the primary series measured for serotypes 6B, 14, 19A and 23F.

						P-value ^a					
		Schedules				2-4-6 vs			3-5 vs		2-3-4 vs
Serotype		2-4-6 (n=40)	3-5 (n=40)	2-3-4 (n=40)	2-4 (n=40)	3-5	2-3-4	2-4	2-3-4	2-4	2-4
6B	GMT (95% CI)	708 (386-1301)	99 (46-211)	551 (371-817)	110 (52-230)	<.001		<.001	.001		.003
	No. (%) $\geq 1:8$	35/38 (92)	27/39 (69)	37/38 (97)	25/34 (74)						
14	GMT (95% CI)	1776 (1211-2603)	1655 (991-2762)	1742 (1227-2474)	1776 (1263-2497)						
	No. (%) $\geq 1:8$	39/39 (100)	38/39 (97)	40/40 (100)	39/39 (100)						
19A	GMT (95% CI)	365 (227-587)	163 (85-312)	309 (201-473)	123 (69-220)	.19		.03	.52		.10
	No. (%) $\geq 1:8$	38/40 (95)	32/39 (82)	38/40 (95)	30/36 (83)						
23F	GMT (95% CI)	1438 (857-2414)	422 (235-760)	537 (309-932)	344 (186-636)	.01	.08	.003			
	No. (%) $\geq 1:8$	38/39 (92)	34/38 (97)	36/39 (89)	31/35 (89)						

N indicates maximum number of infants with available results; actual number of infants included in the analysis varies slightly per serotype. Serum samples with a GMT below the detection limit of 8 were reported as 4 for the purpose of data analyses. ^aDifferences in GMCs between groups were analyzed using ANOVA and corrected for 6 multiple comparisons using Bonferroni. An adjusted p-value of <0.05 is considered statistically significant (in bold).

eTable 3A. Immunogenicity of routine vaccine (DTPa-IPV-Hib) administered at 2, 3, 4 and 11-12 months of age and given concomitantly with or without PCV-13 measured 1 month after the booster dose.

		Schedules							
		2-4-6 (n=92)		3-5 (n=89)		2-3-4 (n=86)		2-4 (n=88)	
Antigen	Threshold (TH)	GMC/T (95% CI)	No. (%) > TH	GMC/T (95% CI)	No. (%) > TH	GMC/T (95% CI)	No. (%) > TH	GMC/T (95% CI)	No. (%) > TH
Diphtheria	IgG \geq 0.10 IU/ml	1.6 (1.4-1.9)	92/92 (100)	1.8 (1.5-2.1)	89/89 (100)	1.4 (1.3-1.6)	86/86 (100)	1.6 (1.4-1.7)	88/88 (100)
Tetanus	IgG \geq 0.10 IU/ml	3.1 (2.6-3.7)	92/92 (100)	3.0 (2.5-3.6)	89/89 (100)	2.7 (2.2-3.2)	86/86 (100)	2.9 (2.4-3.5)	88/88 (100)
Pertussis PT	IgG \geq 20 EU/ml	113 (95-135)	90/92 (98)	132 (112-155)	89/89 (100)	104 (87-124)	82/86 (95)	108 (93-127)	87/88 (99)
Pertussis FHA	-	82 (71-95)	-	96 (83-111)	-	83 (71-98)	-	91 (77-107)	-
Pertussis PRN	-	113 (93-137)	-	139 (112-174)	-	100 (83-120)	-	109 (89-134)	-
Polio Type 1	Titers \geq 1:8	431 (278-670)	83/89 (93)	439 (285-678)	80/86 (93)	233 (143-378)	73/81 (90)	344 (226-524)	82/87 (94)
Polio Type 2	Titers \geq 1:8	1169 (829-1649)	89/89 (100)	1294 (930-1799)	85/86 (99)	740 (506-1082)	81/81 (100)	1109 (787-1563)	85/87 (98)
Polio Type 3	Titers \geq 1:8	1124 (750-1685)	88/89 (99)	1083 (704-1667)	84/86 (98)	651 (394-1074)	74/81 (91)	1386 (924-2080)	84/87 (97)
PRP-Hib	IgG \geq 0.15 μ g/ml	11.6 (8.0-16.6)	88/92 (96)	15.1 (10.4-22.1)	86/89 (97)	11.5 (7.6-17.2)	82/86 (95)	15.0 (11.2-20.1)	88/88 (100)


N indicates maximum number of infants with available results; actual number of infants included in the analysis varies slightly per antigen, depending on serum availability for testing. No significant differences between groups were found.

eTable 3B. Immunogenicity of routine vaccine (DTPa-IPV-Hib) administered at 2, 3, and 4 months of age and given concomitantly with or without PCV-13 measured pre-booster.

		Schedules							
		2-4-6 (n=92)		3-5 (n=89)		2-3-4 (n=86)		2-4 (n=88)	
Antigen	Threshold (TH)	GMC/T (95% CI)	No. (%) > TH	GMC/T (95% CI)	No. (%) > TH	GMC/T (95% CI)	No. (%) > TH	GMC/T (95% CI)	No. (%) > TH
Diphtheria	IgG ≥ 0.10 IU/ml	0.1 (0.1-0.1) ^{A,B}	54/94 (57)	0.1 (0.1-0.1)	40/87 (46)	0.1 (0.1-0.1)	32/86 (37)	0.1 (0.1-0.1)	32/88 (36)
Tetanus	IgG ≥ 0.10 IU/ml	0.2 (0.2-0.2)	73/94 (78)	0.2 (0.1-0.2)	60/87 (69)	0.2 (0.1-0.2)	57/86 (66)	0.2 (0.1-0.2)	61/88 (69)
Pertussis PT	IgG ≥ 20 EU/ml	8 (7-9)	7/94 (7)	9 (8-10)	6/87 (7)	8 (6-9)	9/86 (10)	8 (7-9)	4/88 (5)
Pertussis FHA	-	17 (15-20)	-	20 (16-24)	-	16 (13-19)	-	19 (16-24)	-
Pertussis PRN	-	7 (5-8)	-	9 (7-11)	-	6 (5-8)	-	6 (5-8)	-
Polio Type 1	Titers ≥ 1:8	5 (4-7)	34/91 (37)	6 (4-7)	32/81 (40)	5 (4-6)	32/85 (38)	6 (4-7)	36/86 (42)
Polio Type 2	Titers ≥ 1:8	9 (7-13)	45/92 (49)	16 (11-23) ^C	59/82 (72)	8 (6-11)	45/85 (53)	11 (8-15)	51/86 (59)
Polio Type 3	Titers ≥ 1:8	8 (6-11)	48/91 (53)	9 (6-13)	38/81 (47)	7 (5-10)	37/85 (44)	10 (7-14)	48/86 (56)
PRP-Hib	IgG ≥ 0.15 µg/ml	0.2 (0.1-0.3)	55/94 (59)	0.3 (0.2-0.5)	56/86 (65)	0.2 (0.1-0.3)	54/86 (63)	0.2 (0.2-0.3)	48/88 (55)


N indicates maximum number of infants with available results; actual number of infants included in the analysis varies slightly per antigen, depending on serum availability for testing. Differences between groups were tested using ANOVA. P-value <0.05 after adjustment for 6 multiple comparisons: ^(A) 2-4-6 vs. 2-3-4; ^(B) 2-4-6 vs. 2-4; ^(C) 3-5 vs. 2-3-4 (in bold).

eFigure 1A. Relative cumulative distribution curves of the serotype-specific IgG concentrations per schedule one month post-booster.




The percentage of participants (y axis) is plotted against the IgG concentrations obtained by MIA. Total number of samples per group is 95, 91, 89 and 93 (for 2-4-6, 3-5, 2-3-4 and 2-4 schedule, respectively)

eFigure 1B. Relative cumulative distribution curves of the serotype-specific IgG concentrations per schedule one month post-primary series.



The percentage of participants (y axis) is plotted against the IgG concentrations obtained by MIA. Total number of samples per group is 89, 90, 88 and 89 (for 2-4-6, 3-5, 2-3-4 and 2-4 schedule, respectively)

eFigure 2. Longitudinal course of GMCs after primary series up to the booster per schedule per serotype.



A significantly larger decline in log-concentrations was observed in the first period from the primary series to 8 months as compared to the second period from 8 to 11 months for nearly all comparisons (complete cases analysis, $n=73$, $n=71$, $n=76$, $n=74$ for 2-4-6, 3-5, 2-3-4 and 2-4 schedule, respectively, data not shown). For serotype 6B, the GMC in the 2-4 schedule is 0.088 at 5 months of age.